USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market
A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market
RELEASE DATE
18-Apr-2014
18-Apr-2014
REGION
Global
Global
Research Code: NDDE-01-00-00-00
SKU: LS00124-GL-MR_16965
$3,950.00
In stock
SKU
LS00124-GL-MR_16965
Description
Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline assessment is provided for marketed and investigational products. Segmentation by drug class is provided along with additional supporting information, such as clinical-trial timelines and results, historical and projected launch timelines, regulatory guidelines for clinical trial design and approval, and global epidemiology by region.
Table of Contents
Market Developments Since Q1 2013
Executive Summary
Executive Summary (continued)
Drug Discovery Partnerships
Drug Discovery Partnerships (continued)
Companies to Watch
Methodology and Scope
Obesity Indication Background
Obesity Indication Background (continued)
Obesity Indication Background (continued)
Historical and Projected Timeline for Anti-obesity Drugs
Potential Prescribing Behavior Scenario
Regulators’ Recommendations for Designing Anti-obesity Drug Clinical Trials
Regional Comparison of Drug Approval Requirements
Global Prevalence of Obesity by Region
Global Prevalence of Obesity by Region (continued)
Market Overview—Segmentation
Anti-obesity Prescription Pharmaceuticals Market—Competitive Landscape
Ongoing Phase 3 Trials for Obesity Drugs
Ongoing Post-marketing Trials for Obesity Drugs
Comparative Efficacy of Obesity Drugs
Comparative Efficacy of Obesity Drugs (continued)
Pivotal Trial Programs of Recently Approved Anti-obesity Drugs
Pivotal Trial Programs of Late-stage Anti-obesity Drugs
Pivotal Trial Programs of Late-stage Anti-obesity Drugs (continued)
Marketed Products Synopsis
Marketed Products Synopsis (continued)
Marketed Products Synopsis (continued)
Pipeline Synopsis
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Product Dashboard—Qsymia (phentermine/topiramat ER)
Product Dashboard—Belviq (lorcaserin HCl)
Product Dashboard—Contrave (bupropion SR/ naltrexone SR)
Product Dashboard—Victoza (liraglutide)
Conclusions and Recommendations
Conclusions and Recommendations (continued)
Legal Disclaimer
Decision Support Database—Global Prevalence of Obesity
Decision Support Database—Global Prevalence of Obesity (continued)
Decision Support Database—Global Prevalence of Obesity (continued)
Decision Support Database—Global Prevalence of Obesity (continued)
List of References
The Frost & Sullivan Story
Value Proposition
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline assessment is provided for marketed and investigational products. Segmentation by drug class is provided along with additional supporting information, such as clinical-trial timelines and results, historical and projected launch timelines, regulatory guidelines for clinical trial design and approval, and global epidemiology by region.
| No Index | Yes |
|---|---|
| Podcast | No |
| WIP Number | NDDE-01-00-00-00 |
| Is Prebook | No |